Imugene IUGNF Stock
Imugene Price Chart
Imugene IUGNF Financial and Trading Overview
| Imugene stock price | 0.02 USD |
| Previous Close | 0.08 USD |
| Open | 0.06 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.06 - 0.07 USD |
| 52 Week Range | 0.06 - 0.21 USD |
| Volume | 31.48K USD |
| Avg. Volume | 139.61K USD |
| Market Cap | 436.12M USD |
| Beta (5Y Monthly) | 2.372413 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
IUGNF Valuation Measures
| Enterprise Value | 339.17M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 35.065067 |
| Price/Book (mrq) | 2.121875 |
| Enterprise Value/Revenue | 27.27 |
| Enterprise Value/EBITDA | -8.904 |
Trading Information
Imugene Stock Price History
| Beta (5Y Monthly) | 2.372413 |
| 52-Week Change | -38.27% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.21 USD |
| 52 Week Low | 0.06 USD |
| 50-Day Moving Average | 0.08 USD |
| 200-Day Moving Average | 0.11 USD |
IUGNF Share Statistics
| Avg. Volume (3 month) | 139.61K USD |
| Avg. Daily Volume (10-Days) | 264.71K USD |
| Shares Outstanding | 6.42B |
| Float | 5.18B |
| Short Ratio | N/A |
| % Held by Insiders | 15.40% |
| % Held by Institutions | 9.09% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -324.55% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -13.56% |
| Return on Equity (ttm) | -22.51% |
Income Statement
| Revenue (ttm) | 12.44M USD |
| Revenue Per Share (ttm) | 0.002 USD |
| Quarterly Revenue Growth (yoy) | -10.00000000000000000000000000000000% |
| Gross Profit (ttm) | 12.97M USD |
| EBITDA | -38093488 USD |
| Net Income Avi to Common (ttm) | -40429508 USD |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 161.91M USD |
| Total Cash Per Share (mrq) | 0.03 USD |
| Total Debt (mrq) | 187.56K USD |
| Total Debt/Equity (mrq) | 0.09 USD |
| Current Ratio (mrq) | 48.547 |
| Book Value Per Share (mrq) | 0.032 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -41540920 USD |
| Levered Free Cash Flow (ttm) | -34366272 USD |
Profile of Imugene
| Country | United States |
| State | NSW |
| City | Sydney |
| Address | 4-6 Bligh Street |
| ZIP | 2000 |
| Phone | N/A |
| Website | https://www.imugene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Q&A For Imugene Stock
What is a current IUGNF stock price?
Imugene IUGNF stock price today per share is 0.02 USD.
How to purchase Imugene stock?
You can buy IUGNF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Imugene?
The stock symbol or ticker of Imugene is IUGNF.
Which industry does the Imugene company belong to?
The Imugene industry is Biotechnology.
How many shares does Imugene have in circulation?
The max supply of Imugene shares is 7.58B.
What is Imugene Price to Earnings Ratio (PE Ratio)?
Imugene PE Ratio is now.
What was Imugene earnings per share over the trailing 12 months (TTM)?
Imugene EPS is -0.01 USD over the trailing 12 months.
Which sector does the Imugene company belong to?
The Imugene sector is Healthcare.